There has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Read More
Skip to content
Interest: Early detection and treatment
The Macular Degeneration Foundation has launched a new national awareness campaign that featured symptom recognition.
Read More With a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Read More Research has revealed Australians significantly underestimate the role of family history in developing macular degeneration.
Read More Macular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read More The TGA has approved a new drug, Eylea, for the treatment of wet (neovascular) age-related macular degeneration.
Read More Dame Judi Dench has revealed a diagnosis of age-related macular degeneration.
Read More We reviewed the results of the CATT study, designed to compare two drugs Lucentis (ranibizumab) and Avastin (bevacizumab) used to treat wet AMD.
Read More There is no compelling evidence-based research that hyperbaric oxygen treatment has a beneficial effect on AMD.
Read More